ABRAXANE® (generic name: nab-paclitaxel) was approved by the FDA as first-line therapy for the metastatic adenocarcinoma of the pancreas when used in combination with gemcitabine. The approval of ABRAXANE is a major development in pancreatic cancer care and is expected to replace gemcitabine alone as a new standard of care for pancreatic cancer.
Oncology targets, strategies, cancer drug development and personalized medicine
Showing posts with label abraxane. Show all posts
Showing posts with label abraxane. Show all posts
Friday, September 6, 2013
Thursday, March 3, 2011
Helping Win Steve Jobs' Pancreatic Cancer Fight For All of US Because iPads Are Not the Only Things That Matter
Yesterday, Steve Jobs once again returned to the world stage to introduce Apple's new iPad2 and once again the spotlight was also put on his ongoing battle with pancreatic cancer.
Wednesday, October 13, 2010
Old Drugs have a lot more Firepower
Celgene Corporation (NASDAQ:CELG) was in the news a few months ago for buying Abraxis BioScience for 2.9 billion (read: A Billionaire’s Biotech Deal And Old Drugs Reborn at forbes.com, or Prominent Drug Chief to Sell Abraxis BioScience to Celgene for $2.9 Billion at nytimes.com) With this purchase, Celgene has become a big player in the Oncology biz-space with two re-incarnated drugs:
Subscribe to:
Posts (Atom)